Leowattana W, Pokum S, Mahanonda N, Poungvarin N
Department of Clinical Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 2001 Dec;84 Suppl 3:S658-68.
Several recent reports including serological, pathological and animal studies have associated Chlamydia pneumoniae with coronary artery disease (CAD). In order to establish whether chronic C. pneumoniae infection is linked to coronary artery disease, clinical intervention trials may be needed. However, to detect eligible patients with persistent infection, a reliable diagnostic marker must be developed for identifying cases and assessing efficacy of antichlamydial therapy. Moreover, the prevalence of circulating C. pneumoniae DNA in CAD patients varied widely from previous reports. A real-time PCR has been established by using HL-1 and HR-1 primer to amplify 437 base pairs product. Confirmation of the product was performed on LightCycler by melting curve analysis of detection probes labeled with LC-Red705. Ninety-five angiographically confirmed CAD patients and 104 normal, healthy volunteers were recruited. The mononuclear cell layer was separated from collected blood and rapid, single step real-time PCR was used to detect C. pneumoniae DNA. C. pneumoniae DNA in peripheral blood mononuclear cells (PBMC) was found in 17 per cent of 95 CAD patients and 1 per cent of 104 normal healthy volunteers (odds ratio 20.86, 95% confidence interval 2.71 - 160.67, p < 0.0001). There was no association between C. pneumoniae DNA in PBMC and serological status. The rapid, real-time PCR showed a clear-cut result between positive and negative cases. PBMC-based real-time PCR may be a useful tool for identifying subjects carrying C. pneumoniae in the circulation or in the vascular wall as well. It will be a specific indicator of current infection and will be used as a marker for assessing the microbiological efficacy of antichlamydial therapy in clinical intervention trials.
包括血清学、病理学和动物研究在内的多项近期报告将肺炎衣原体与冠状动脉疾病(CAD)联系起来。为了确定慢性肺炎衣原体感染是否与冠状动脉疾病有关,可能需要进行临床干预试验。然而,为了检测持续感染的合格患者,必须开发一种可靠的诊断标志物,用于识别病例并评估抗衣原体治疗的疗效。此外,CAD患者中循环肺炎衣原体DNA的患病率与先前报告相比差异很大。通过使用HL-1和HR-1引物建立了实时PCR,以扩增437个碱基对的产物。通过对标记有LC-Red705的检测探针进行熔解曲线分析,在LightCycler上对产物进行确认。招募了95例经血管造影证实的CAD患者和104名正常健康志愿者。从采集的血液中分离出单核细胞层,并使用快速单步实时PCR检测肺炎衣原体DNA。在95例CAD患者中有17%在外周血单核细胞(PBMC)中发现了肺炎衣原体DNA,而在104名正常健康志愿者中有1%发现了该DNA(优势比为20.86,95%置信区间为2.71 - 160.67,p < 0.0001)。PBMC中的肺炎衣原体DNA与血清学状态之间没有关联。快速实时PCR在阳性和阴性病例之间显示出明确的结果。基于PBMC的实时PCR可能是一种有用的工具,可用于识别循环系统或血管壁中携带肺炎衣原体的个体。它将是当前感染的一个特异性指标,并将在临床干预试验中用作评估抗衣原体治疗微生物学疗效的标志物。